2023 New York Laws › PBH - Public Health › Article 25 - Maternal and Child Health › Title 1 - General Provisions › 2500-A - Test for Phenylketonuria and Other Diseases and Conditions.

§  2500-a. Test for phenylketonuria and other diseases and conditions.
1. It shall be the duty of the administrative officer or other person in
charge of each institution caring for infants twenty-eight days or  less
of age and the person required in pursuance of the provisions of section
forty-one  hundred  thirty  of  this  chapter to register the birth of a
child, to cause to have administered to every such infant  or  child  in
its  or  his  care  a test for diseases and conditions designated by the
commissioner under regulations of the commissioner, and for:
(a) Phenylketonuria.
(b) Homozygous sickle cell disease.
(c) Hypothyroidism.
(d) Branched-chain ketonuria.
(e) Galactosemia.
(f) Homocystinuria.
(g)  Critical  congenital  heart  defects   through   pulse   oximetry
screening.
(h)  With  regard  to  any  newborn  infant  who  is identified as, or
suspected of, having a hearing impairment as a  result  of  a  screening
conducted  pursuant  to  section  twenty-five hundred-g of this title, a
urine polymerase chain reaction (PCR) test for  cytomegalovirus,  unless
the  parent  of  the  infant  objects  thereto;  provided  that  if  the
commissioner  determines  that  another  test  for  cytomegalovirus   is
diagnostically  equivalent  to or better than the urine polymerase chain
reaction test, the commissioner may, by regulation under  this  section,
allow or require the use of that other test.
(i) Adrenoleukodystrophy.
(j)  Glucose-6-phosphate dehydrogenase deficiency using a quantitative
enzymatic test or other diagnostic test  in  cases  where:  the  newborn
infant   presents   with   hemolytic   anemia,  hemolytic  jaundice,  or
early-onset increasing neonatal jaundice, that is,  jaundice  (bilirubin
level  greater  than  fortieth  percentile  for age in hours) persisting
beyond the day of birth through the week after birth; the newborn infant
has been admitted to the hospital for jaundice following birth;  or  the
biological  parent  of the newborn infant indicates a family, racial, or
ethnic risk of glucose-6-phosphate dehydrogenase  deficiency,  including
having  significant  African,  Asian,  Mediterranean,  or Middle Eastern
ancestry.
(k)  Duchenne  muscular  dystrophy  using  a  test  validated  by  the
Wadsworth center for laboratories and research.
2.  Testing,  the  recording  of  the results of such tests, tracking,
follow-up reviews and educational activities shall be performed at  such
times  and  in such manner as may be prescribed by the commissioner. The
commissioner shall promulgate regulations setting forth  the  manner  in
which  information  describing  the purposes of the requirements of this
section shall be disseminated to parents or a  guardian  of  the  infant
tested.
3.  The  provisions of this section shall not apply in the case of any
infant or child whose parent or guardian is a  member  of  a  recognized
religious  organization  whose  teachings and tenets are contrary to the
testing herein required and who notifies the person charged with  having
such test administered of his objection thereto.